📇 Rhumatologue · PARIS · (75) · Salarié

MME EMMANUELLE PLAISIER

Pourquoi vous devez consulter ce praticien

3 raisons identifiées

Auteur de référence en rhumatologie
29 articles scientifiques publiés — un praticien à la pointe de la recherche
Expérience confirmée
21 ans d'exercice en rhumatologie — recul clinique solide
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 PARIS (75)SalariéRPPS 10001469138

Expérience confirmée

21ans d'exercice (thèse 2005)

📊 Reconnaissance scientifique : 35/100📝 135 articles publiés🇫🇷 Publications académiques françaises (8)

✨ Génération du profil synthétique IA en cours…

Thèses universitaires

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up

Journal of the American Society of Nephrology : JASN · 2017

📚 319 citations🎯 RCR 13.84Top 1% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Randomized trials of rituximab in primary membranous nephropathy (PMN) have not been conducted. We undertook a multicenter, randomized, controlled trial at 31 French hospitals (NCT01508468). Patients with biopsy-proven PMN and nephrotic syndrome after 6 months of nonimmunosuppressive antiproteinuric treatment (NIAT) were randomly assigned to 6-month therapy with NIAT and 375 mg/m2 intravenous rituximab on days 1 and 8 (n=37) or NIAT alone (n=38). Median times to last follow-up were 17.0 (interquartile range, 12.5–24.0) months and 17.0 (interquartile range, 13.0–23.0) months in NIAT-rituximab and NIAT groups, respectively. Primary outcome was a combined end point of complete or partial remission of proteinuria at 6 months. At month 6, 13 (35.1%; 95% confidence interval [95% CI], 19.7 to 50.5) patients in the NIAT-rituximab group and eight (21.1%; 95% CI, 8.1 to 34.0) patients in the NIAT group achieved remission (P=0.21). Rates of antiphospholipase A2 receptor antibody (anti–PLA2R-Ab) depletion in NIAT-rituximab and NIAT groups were 14 of 25 (56%) and one of 23 (4.3%) patients at month 3 (P<0.001) and 13 of 26 (50%) and three of 25 (12%) patients at month 6 (P=0.004), respectively. Eight serious adverse events occurred in each group. During the observational phase, remission rates before change of assigned treatment were 24 of 37 (64.9%) and 13 of 38 (34.2%) patients in NIAT-rituximab and NIAT groups, respectively (P<0.01). Positive effect of rituximab on proteinuria remission occurred after 6 months. These data suggest that PLA2R-Ab levels are early markers of rituximab effect and that addition of rituximab to NIAT does not affect safety.

The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy

Kidney international · 2021

📚 170 citations🎯 RCR 13.40Top 2% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

The spectrum of type I cryoglobulinemia vasculitis: new insights based on 64 cases

Medicine · 2013

📚 132 citations🎯 RCR 5.19Top 7% NIH

Cookies & analyse de trafic

MME EMMANUELLE PLAISIER

Pourquoi vous devez consulter ce praticien

Thèses universitaires

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (29) — classées par pathologie

Transversal11

Biothérapies non-anti-TNF7

Case report / série4

Revue générale3

Biomarqueurs / Auto-Ac1

Économie santé1

Épidémiologie & registres1

Maladie à IgG41

Revue / méta-analyse1

Vascularites des gros vaisseaux1

Partager cette fiche